Status:
COMPLETED
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment
Lead Sponsor:
Mansoura University
Conditions:
Chronic Myelogenous Leukemia, BCR-ABL Positive
CML, Chronic Phase
Eligibility:
All Genders
20-60 years
Phase:
PHASE2
Brief Summary
Assessment of patients response and expression levels of CITED2 and HIF2a genes on adding pioglitazone to imatinib therapy.
Detailed Description
Eligible denovo CML patients will be treated by combination drug therapy of imatinib 400 mg plus pioglitazone (15 - 30mg).They will be on follow up for their complete blood count (CBC), chemistry prof...
Eligibility Criteria
Inclusion
- CML cases (BCR-ABL1 positive)
Exclusion
- Accelerated or blastic crisis
- Atypical CML (BCR-ABL1 negative)
- Chronic myelomonocytic leukemia (CMML)
- Pregnant or breastfeeding females.
- Patients with severe organ dysfunction
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04883125
Start Date
January 1 2018
End Date
April 15 2021
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Al Mansurah, Dakahlia Governorate, Egypt, 35511